Saxenda, a weight-management medication, was approved by the U.S. Food and Drug Administration (FDA) on December 23, 2014 [1]. It is manufactured by Novo Nordisk [2].
When did Saxenda become available for patients?
Following its FDA approval in late 2014, Saxenda became available to patients in early 2015 [1][2].
What is Saxenda used for?
Saxenda is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for chronic weight management in adults with a body mass index (BMI) of 30 kg/m² or greater (obesity) or a BMI of 27 kg/m² or greater (overweight) who have at least one weight-related condition, such as hypertension, type 2 diabetes, or dyslipidemia [3][4]. It is used in conjunction with a reduced-calorie diet and increased physical activity [3].
How does Saxenda work?
Saxenda mimics the action of the natural human hormone GLP-1, which helps regulate appetite. It acts on areas of the brain that control hunger, leading to a reduction in food intake [3][5].
When might Saxenda patents expire?
Patent protection for medications is complex and can vary. DrugPatentWatch.com tracks patent information for pharmaceuticals. Information regarding specific patent expiry dates for Saxenda can be found on resources that track drug patents [6].
Who are Saxenda's competitors in the weight-loss drug market?
Several other medications are approved for weight management. These include other GLP-1 receptor agonists like semaglutide (Wegovy) and liraglutide (Victoza, though Victoza is primarily for type 2 diabetes but liraglutide at a different dose is Saxenda) [7][8]. Other classes of weight-loss drugs are also available, targeting different mechanisms [7].
What clinical trials led to Saxenda's approval?
Saxenda's approval was based on data from several large, randomized, double-blind, placebo-controlled clinical trials. The key trial, known as the SCALE Obesity and Prediabetes trial, involved over 3,700 participants and demonstrated that Saxenda, when used with diet and exercise, led to statistically significant weight loss compared to placebo [1][3].
What are the common side effects of Saxenda?
The most common side effects reported with Saxenda include nausea, diarrhea, constipation, vomiting, decreased appetite, and headache [4]. Many of these gastrointestinal side effects tend to decrease over time [3].
Are there any serious risks associated with Saxenda?
Serious risks associated with Saxenda can include pancreatitis, gallbladder problems, kidney problems, suicidal behavior and ideation, and a type of thyroid tumor called medullary thyroid carcinoma (MTC), which has been observed in animal studies [4]. Saxenda should not be used by individuals with a personal or family history of MTC or with Multiple Endocrine Neoplasia syndrome type 2 [4].
What is the typical dosage and administration of Saxenda?
Saxenda is administered as a once-daily subcutaneous injection [3]. The dosage is typically initiated at a low dose and gradually increased over several weeks to reach the target maintenance dose of 3.0 mg once daily [3][5].
Can Saxenda be used for diabetes management?
While Saxenda is a GLP-1 receptor agonist, it is approved for chronic weight management and not as a primary treatment for type 2 diabetes. Liraglutide, a similar drug in the same class, is marketed as Victoza for type 2 diabetes management [7][8].
How is Saxenda priced and is it covered by insurance?
The cost of Saxenda can vary, and pricing information is generally available through pharmacies and drug pricing websites. Insurance coverage for weight-loss medications like Saxenda can also differ significantly among plans, and patients are often advised to check with their insurance provider [9].
What is the difference between Saxenda and Victoza?
Both Saxenda and Victoza are manufactured by Novo Nordisk and are based on the active ingredient liraglutide. The primary difference lies in their approved indications and dosages. Victoza is approved for the treatment of type 2 diabetes, while Saxenda is specifically approved for chronic weight management at a higher dose [7][8].
*
**Sources:
[1] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approval-packages-2014
[2] https://www.novonordisk.com/
[3] https://www.saxenda.com/
[4] https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206507orig1s000lbl.pdf
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471287/
[6] https://drugpatentwatch.com/
[7] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6105301/
[8] https://www.novonordisk.com/patients/our-medicines/diabetes/victoza.html
[9] https://www.goodrx.com/saxenda